ALYREF and prostate adenocarcinoma: Among the 10 tumor types (ACC, BLCA, KICH, KIRP, LGG, LIHC, LUAD, MESO, PAAD and PRAD), high expression of ALYREF was associated with poor prognosis, whereas the 3 tumor types (DLBC, THYM, OV) with low expression of ALYREF exhibited a similar unfavorable prognosis (Fig. 1C).